SGIOF News and Press, Shionogi & Co Ltd From 05/11/23

2023-05-11 12:44:17 ET Shionogi & Co. ( OTCPK:SGIOF ): FY GAAP EPS of ¥621.31. Revenue of ¥426.7B For further details see: Shionogi & Co. GAAP EPS of ¥621.31, revenue of ¥426.7B

2023-03-30 12:05:56 ET A federal judge on Thursday struck down a key provision in the Affordable Care Act (ACA) that requires health plans to provide free coverage for preventive care, including pre-exposure prophylaxis drugs for HIV (PrEP) and cancer screenings. District Court Judg...

2023-03-30 05:13:16 ET The United Nations-backed Medicines Patent Pool (MPP) signed agreements with Aurobindo, Cipla and Viatris ( NASDAQ: VTRS ) to produce generic versions of ViiV Healthcare's long-acting HIV prevention medicine. ViiV — which is majority o...

Summary Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside. However, this allows Shionogi to be the next great COVID opportunity, offering both significant profit generation for shareholder benefit an...

Shionogi & Co. ( OTCPK:SGIOF ): Q3 Revenue of ¥338.3B. Operating profit ¥146.5B For further details see: Shionogi & Co. reports Q3 results

Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Conference Call January 30, 2023 1:00 AM ET Company Participants Yoshimasa Kyokawa - Investor Relations Masako Kudou - Vice President, Finance and Accounting Department Ryuichi Kiyama - Senior Executive Officer and Seni...

Japanese drugmaker Shionogi ( OTCPK:SGIOF ) ( OTCPK:SGIOY ) announced Tuesday that the company won a contract from the government of Japan to supply additional 1M courses of its oral COVID-19 antiviral Xocova. Xocova, a collaboration between Shionogi ( OTCPK:SGIOF ) and Hokkaido...

Shionogi & Co., Ltd. (SGIOF) Q1 2022 Earnings Conference Call August 1, 2022 01:45 ET Company Participants Yoshimasa Kyokawa - Investor Relations John Keller - Senior Executive Officer and Senior Vice President, R&D Supervisory Unit Toshinobu Iwasaki - Se...

Shionogi & Co. press release ( OTCPK:SGIOF ): Q1 GAAP EPS of ¥115.13. Revenue of ¥71.84B (+4.2% Y/Y). For further details see: Shionogi & Co. GAAP EPS of ¥115.13, revenue of ¥71.84B

A group of health experts in Japanese health ministry delayed emergency approval on Wednesday for the COVID-19 pill developed by Osaka-based drugmaker Shionogi & Co. ( OTCPK:SGIOF ) ( OTCPK:SGIOY ), citing the need to continue discussions on the drug. The delay marks the...